About Overactive Bladder
Overactive bladder is a urological condition associated with urination problems. The condition is characterized by bladder storage symptoms such as urgency, change in frequency of urination, nocturia, or urinary incontinence. It is also known as overactive bladder syndrome. Although it is not a life-threatening condition, it is often stigmatized and debilitating. Some of the important symptoms of overactive bladder are urinary urgency and incontinence. The pathophysiology of overactive bladder is not characterized completely. The symptoms of overactive bladder can last for a lifetime or it can relapse and remit. The problem can be resolved through treatment. Overactive bladder can affect a person irrespective of the gender. The reason is the abnormal contraction of the urinary detrusor muscle of the bladder. In addition, overactive bladder can be related to neurological diseases such as Parkinson's disease and multiple sclerosis.
TechNavio's analysts forecast the Global Overactive Bladder Therapeutics market to grow at a CAGR of 1.14 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Overactive Bladder Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of overactive bladder, which include:
• Anti-muscarinic Agent
• Beta-3-Adrenergic Receptor Agonist
TechNavio's report, Global Overactive Bladder Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Overactive Bladder Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Actavis
• Allergan
• Astellas Pharma
• Pfizer
Other Prominent Vendors
• Addex Therapeutics
• AltheRx Pharmaceuticals
• American Oriental Bioengineering
• Antares Pharma
• Apogepha Arzneimittel
• Auxilium Pharmaceuticals
• Bayer
• elbion
• FemmePharma
• Ferring Pharmaceuticals
• GlaxoSmithKline
• Hisamitsu Pharmaceutical
• Hydra Biosciences
• Ion Channel Innovations
• Ipsen
• Janssen
• Kissei Pharma
• Kwang Dong Pharmaceutical
• KYORIN Pharma
• Laboratorios SALVAT
• LG Life Sciences
• Lipella Pharmaceuticals
• Merck
• Motif BioSciences
• Mylan
• Novartis
• Ono Pharmaceuticals
• Ranbaxy Laboratories
• Recordati
• Sanofi
• Sunovion
• Takeda Pharmaceutical
• TARIS BioMedical
• Teva Pharmaceutical
• TheraVida
• Toray Industries
• Urigen Pharmaceuticals
Market Driver
• Rise in Geriatric Population
• For a full, detailed list, view our report
Market Challenge
• Difficulty in Disease Diagnosis
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Enablex/Emselex
04.1.2 Gelnique
04.1.3 Oxytrol
04.1.4 Botox
04.1.5 Sanctura/ Sanctura XR
04.1.6 Myrbetriq
04.1.7 Vesicare
04.1.8 Detrol/Detrol LA
04.1.9 Toviaz
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Molecule Type
08.1 Biologics
08.2 Small Molecules
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
09.3 Topical
10. Market Segmentation by Class of drugs
10.1 Anti-muscarinic Agent
10.2 Beta-3-Adrenergic Receptor Agonist
11. Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
11.3 Semisolid
11.4 Transdermal
12. Rate of Incidence and Prevalence
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.2.1 Actavis
21.2.2 Allergan
21.2.3 Astellas Pharma
21.2.4 Pfizer
21.3 Other and Future Prominent Vendors
22. Pipeline Portfolio
23. Key Vendor Analysis
23.1 Actavis plc
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.2 Allergan Inc.
23.2.1 Key Facts
23.2.2 Business Description
23.2.3 Business Segmentation
23.2.4 Revenue by Business Segmentation
23.2.5 Revenue Comparison 2011-2013
23.2.6 Revenue by Geographical Segmentation
23.2.7 Business Strategy
23.2.8 Key Developments
23.2.9 SWOT Analysis
23.3 Astellas Pharma
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Product Segmentation
23.3.4 Product Segmentation by Revenue 2012 and 2013
23.3.5 Geographical Segmentation by Revenue 2013
23.3.6 Business Strategy
23.3.7 Recent Developments
23.3.8 SWOT Analysis
23.4 Pfizer
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2012 and 2013
23.4.5 Geographical Segmentation by Revenue
23.4.6 Business Strategy
23.4.7 Key Developments
23.4.8 SWOT Analysis
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Overactive Bladder Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Global Overactive Bladder Therapeutics Market Segmentation by Molecule Type
Exhibit 4: Global Overactive Bladder Therapeutics Market Segmentation by Molecule Type 2013
Exhibit 5: Global Overactive Bladder Therapeutics Market Segmentation by Route of Administration
Exhibit 6: Global Overactive Bladder Therapeutics Market Segmentation by Route of Administration 2013
Exhibit 7: Global Overactive Bladder Therapeutics Market Segmentation by Class of Drugs
Exhibit 8: Global Overactive Bladder Therapeutics Market Segmentation by Class of Drugs 2013
Exhibit 9: Global Overactive Bladder Therapeutics Market Segmentation by Dosage Form
Exhibit 10: Global Overactive Bladder Therapeutics Market Segmentation by Dosage Form 2013
Exhibit 11: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2013
Exhibit 12: Global Overactive Bladder Therapeutics Market Share Analysis 2013
Exhibit 13: Prescription chart
Exhibit 14: By drugs prescribed (up to 2011)
Exhibit 15: YoY Sales Comparison of Botox 2008-2013 (in US$ million)
Exhibit 16: YoY Sales Comparison of Vesicare 2008-2013 (in US$ million)
Exhibit 17: YoY Sales Comparison of Vesicare in Japan 2008-2013 (in US$ million)
Exhibit 18: YoY Sales Comparison of Vesicare in the Americas 2008-2013 (in US$ million)
Exhibit 19: YoY Sales Comparison of Vesicare in Europe 2008-2013 (in US$ million)
Exhibit 20: YoY Sales Comparison of Vesicare in Asia 2008-2013 (in US$ million)
Exhibit 21: Sales Comparison of Vesicare 2008-2013 (in US$ million)
Exhibit 22: YoY Sales Comparison of Detrol/Detrol LA 2009-2013 (in US$ million)
Exhibit 23: YoY Sales Comparison of Toviaz 2009-2013 (in US$ million)
Exhibit 24: Pipeline Molecules for the Treatment of Overactive Bladder
Exhibit 25: Global Overactive Bladder Therapeutics Market Business Segmentation 2013
Exhibit 26: Global Overactive Bladder Therapeutics Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 27: Actavis Plc: Sales by Geography (in US$ million)
Exhibit 28: Allergan Inc.: Business Segmentation
Exhibit 29: Allergan Inc.: Revenue by Business Segmentation 2013
Exhibit 30: Allergan Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ billion)
Exhibit 31: Allergan Inc.: Revenue by Geographical Segmentation 2013
Exhibit 32: Astellas Pharma: Product Segmentation 2013
Exhibit 33: Astellas Pharma: Product Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 34: Astellas Pharma: Geographical Segmentation by Revenue 2013
Exhibit 35: Pfizer: Business Segmentation by Revenue 2013
Exhibit 36: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 37: Pfizer: Geographical Segmentation by Revenue 2013
